Bone Biologics Corp. (NASDAQ:BBLG) Short Interest Update
by Amy Steele · The Cerbat GemBone Biologics Corp. (NASDAQ:BBLG – Get Free Report) was the recipient of a significant drop in short interest in May. As of May 15th, there was short interest totaling 2,897 shares, a drop of 72.2% from the April 30th total of 10,427 shares. Based on an average daily trading volume, of 9,614 shares, the short-interest ratio is presently 0.3 days. Currently, 0.2% of the company’s stock are sold short.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings raised shares of Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, April 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.
Get Our Latest Analysis on BBLG
Bone Biologics Price Performance
BBLG opened at $1.32 on Friday. The company’s 50-day moving average is $1.26 and its 200 day moving average is $1.44. Bone Biologics has a fifty-two week low of $1.05 and a fifty-two week high of $6.75. The firm has a market capitalization of $2.38 million, a P/E ratio of -0.58 and a beta of 0.89.
Bone Biologics (NASDAQ:BBLG – Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.43) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.43). On average, equities research analysts expect that Bone Biologics will post -1.52 earnings per share for the current year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Bone Biologics stock. DRW Securities LLC lifted its position in shares of Bone Biologics Corp. (NASDAQ:BBLG – Free Report) by 113.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,576 shares of the company’s stock after purchasing an additional 12,549 shares during the period. DRW Securities LLC owned 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. 34.30% of the stock is currently owned by hedge funds and other institutional investors.
About Bone Biologics
Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.
Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.